China sets launch of asteroid probe Tianwen-2 for late May, state media reports
BEIJING, May 18 (Reuters) - China is preparing to launch near-Earth asteroid probe Tianwen-2 at the end of May, state-run CCTV reported on Sunday, in the country's first mission to collect samples from interplanetary space.
Tianwen-2 was transported to the Xichang Satellite Launch Centre's launch area on May 14 and will take off after passing inspections, the report said.
The craft will use a mechanical arm to scoop up dust samples from the surface of 2016 HO3, a small 100-m (328-ft) asteroid that circles Earth like a "quasi-satellite". It will also explore 311P, a comet.
Other nations including the U.S. and Japan have successfully landed on asteroids.
A space race between China and the U.S. has led to the launch of new exploration plans in recent years.
In 2024, China became the first nation to bring back samples from the moon's far side with its Chang'e-6 lunar probe.
Around 2028, China's Tianwen-3 mission will attempt to bring back samples from Mars.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
7 hours ago
- Daily Mail
Statins almost halve the risk of death in patients critically ill with sepsis
Taking statins can improve the chances of surviving sepsis by 40 per cent, a trial has found. Sepsis can occur when the body's immune system overreacts to an infection and attacks its own organs. It is notoriously difficult to spot because the telltale symptoms, such as a fever and muscle pain, can be easily mistaken for signs of a common cold or other infection. Statins lower cholesterol to prevent heart attacks and strokes and are taken by around 5 million adults in the UK. But experts say they have other benefits, including reducing inflammation and fighting bacteria that can ultimately lead to sepsis. The study compared survival rates of sepsis patients given statins and those who were not during a hospital stay. It found the pills reduced the risk of death for those critically ill with the condition by 39 per cent. The study compared survival rates of sepsis patients given statins and those who were not during a hospital stay. It found the pills reduced the risk of death for those critically ill with the condition by 39 per cent (file image) In intensive care, 14.3 per cent of 6,000 sepsis patients given statins died within 28 days, compared with 23.4 per cent of 6,000 patients who were not. For those no longer in a critical condition, 11 per cent given statins died compared to 19 per cent who were not. Dr Caifeng Li, of Tianjin Medical University General Hospital in China and the study's author said: 'These results suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Researchers believe the drugs may help with sepsis by helping to combat bacteria directly, reducing the toll infection takes on the body. Earlier this year another study found the pills could also slash dementia risk – even in patients who don't have high cholesterol. The sepsis study, published in the journal Frontiers in Immunology, was based on data from thousands of patients at an Israeli hospital over a decade. Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'This study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.' Sepsis is known as the 'silent killer'. For every hour of delay in treatment, a patient's chance of dying increases 8 per cent. If caught early, it can be treated with antibiotics and fluids. Symptoms include slurred speech or confusion, shivering or muscle pain, passing no urine in a day, severe breathlessness and mottled or discoloured skin. Blood test to spot Alzheimer's early A Blood test for Alzheimer's can accurately detect the disease early, a study suggests. The test was 95 per cent accurate in identifying people with memory problems. It also scored 82 per cent for specificity, which means it was highly accurate in ruling out people without dementia. The study, published in the journal Alzheimer's and Dementia, found proteins amyloid beta 42/40 and p-tau217 in blood plasma can be examined to diagnose the condition. The study was carried out on more than 500 people in an outpatient memory clinic. The blood test has already been approved by the Food and Drug Administration regulator in the US.
The Independent
11 hours ago
- The Independent
New coronavirus discovered in China ‘only small step' from infecting humans
A new coronavirus discovered in China is only a small step from mutating and causing another global pandemic, experts have warned. Scientists believe the variant, called HKU5-CoV-2, may infect a broader range of animals than Covid-19 – which caused millions of deaths – and may have more potential for jumping between species. US researchers fear that HKU5-CoV-2, found in China, in February, could also infect humans, leading to a widespread outbreak. The new study, published in Nature Communications, looked at a lesser-known group of coronaviruses called merbecoviruses, which includes HKU5 and MERS-CoV, which is responsible for the deadly Middle East Respiratory Syndrome. The team from Washington State University looked at how the new pathogen interacts with human cells. They found that a small change in the virus's spike protein could allow it to attach to human ACE2 cells in people's throats, mouths and noses. HKU5-CoV-2 can infect and replicate inside human cells in both the airways and gut. According to the World Health Organisation, about 35 per cent of people infected with Middle East Respiratory Syndrome die. Since 2012, some 27 countries have reported cases, leading to 858 known deaths due to the infection, which spread from camels. But when HKU5 was discovered in February, scientists warned against exaggerating the risks because it does not enter human cells as readily as Sars-CoV-2, which caused Covid-19. HKU5 was first detected in bats by scientists from the Chinese laboratory where some say Covid originated in 2019. Prof Michael Letko, a virologist who co-led the study, said: 'HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. 'What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans.' When Covid-19 emerged it was widely blamed on markets in China where different breeds of wild animal are kept caged and often slaughtered close to other animals. Meat is sold at the open-air stalls. Critics said the markets were the perfect breeding ground for new zoonotic diseases – those that spread to humans – to emerge. The scientists, whose experiments studied how the new pathogen interacts with human cells, believe the virus would have to carry certain mutations if it were to infect humans. 'These viruses are closely related to MERS, so we have to be concerned if they ever infect humans,' Prof Letko said. 'While there's no evidence they've crossed into people yet, the potential is there and that makes them worth watching.'
The Independent
19 hours ago
- The Independent
This common prescription drug could reduce deaths by sepsis, study finds
Critically ill patients with sepsis who are given statins may be more likely to survive, new research suggests. Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients. The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year. UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
